предыдущий|следующий

A clinical efficacy study of Yangyin Shugan Decoction to treat premature ovarian insufficiency based on real-world evidence

  • role： First author第一作者
  • Affiliation：

    The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China

  • Introduction：黄旭春，女，硕士，主任医师
HUANG Xuchun1,  
  • Affiliation：

    Guangzhou University of Chinese Medicine, Guangzhou 510405, China

LI Lingtong2,  
  • Affiliation：

    Guangzhou University of Chinese Medicine, Guangzhou 510405, China

HOU Jiarui2,  
  • Affiliation：

    Guangzhou University of Chinese Medicine, Guangzhou 510405, China

LIANG Na2,  
  • Affiliation：

    The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China

CAO Xiaojing1,  
  • Affiliation：

    The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China

CHENG Fangping1,  
  • Affiliation：

    The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China

LAO Yingrong1,  
  • role： Corresponding author通信作者
  • Affiliation：

    The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China

  • Email：xiaocat78@126.com
  • Introduction：Prof. WANG Xiaoyun, Chief Physician, Doctoral Supervisor. The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Training Building, Guangzhou 510120.E-mail: xiaocat78@126.com
WANG Xiaoyun1*

реферат

ObjectiveBased on the real-world data, we aimed to study the clinical efficacy and safety of Yangyin Shugan (method of nourishing yin and soothing liver) Decoction, an empirical prescription of famous traditional Chinese medicine (TCM) practitioners, in the treatment of premature ovarian insufficiency (POI) with pattern of kidney deficiency and liver depression.MethodsA total of 618 POI patients with pattern of kidney deficiency and liver depression who registered in the outpatient electronic medical record system of Guangdong Provincial Hospital of Chinese Medicine were collected from January 2020 to December 2023. After 1: 1 propensity matching, a total of 222 patients with POI who met the criteria were included and assigned to a Yangyin Shugan Decoction group (treated with Yangyin Shugan Decoction only) and a hormone control group (hormone treatment only), with 111 cases in each group. Age, age at menarche, marriage status, duration, times of pregnancy, times of miscarriage, menstrual total score, total score of TCM syndrome, basal serum follicle-stimulating hormone (bFSH), and anti-Müllerian hormone (AMH) were recorded and compared. After 3 to 4 months of treatment, the clinical efficacy between the two groups include TCM syndromes, menstrual, bFSH, and menstrual normalization rates during the follow-up period (3 months after discontinuation of medication) were compared. Additionally, comparisons were also made before and after treatment for the total score of TCM syndrome and scores of individual symptom, menstrual total score and scores of indicator, bFSH level, and AMH levels in both groups.Results(ⅰ)The total effective rate of the TCM syndrome in the Yangyin Shugan Decoction group and hormone control group were 85.59% and 52.25%, respectively; the total effective rate of menstrual were 54.95% and 90.99%, respectively; the menstrual normalization rate during the follow-up period were 31.53% and 9.01%, respectively; and regarding bFSH efficacy, the total effective rate were 70.27% and 27.03%, respectively, and the normalization rate of bFSH were 35.14% and 9.01%, respectively. The differences between the two groups were statistically significant (P<0.01). (ⅱ)The bFSH value in the Yangyin Shugan Decoction group decreased after treatment compared to before treatment(P<0.01), while the bFSH value in the hormone control group showed no change before and after treatment. The AMH value increased after treatment compared to before treatment in Yangyin Shugan Decoction group(P<0.01), while the AMH value in the hormone control group showed no change before and after treatment. The difference of bFSH and AMH between the two groups after treatment was statistically significant (P<0.01). (ⅲ)After treatment, the total score of TCM syndrome and the scores of individual symptom in the Yangyin Shugan Decoction group were lower than those before treatment(P<0.01); the total score of TCM syndrome, scores of hot flushes and sweating, hyposexuality, and insomnia in the hormone control group were lower than those before treatment (P<0.01). After treatment, the total score of TCM syndrome and the scores of individual symptom in the Yangyin Shugan Decoction group were lower than those in the hormone control group (P<0.01). (ⅳ)After treatment, the menstrual total score, scores of menstrual cycle, period, menstrual flow, and menstrual blood color in the Yangyin Shugan Decoction group were lower than those before treatment (P<0.01); the menstrual total score, score of menstrual cycle, period, and menstrual flow in the hormone control group were lower than those before treatment (P<0.01); after treatment, the menstrual total score and menstrual cycle score in the hormone control group were better than those in the Yangyin Shugan Decoction group (P<0.01).(ⅴ)No adverse reactions were observed in the Yangyin Shugan Decoction group and 29 cases of adverse reactions were observed in the hormone control group.ConclusionYangyin Shugan Decoction can effectively improve TCM syndrome in POI patients with pattern of kidney deficiency and liver depression; downregulate the elevated bFSH level, increase the low AMH level, and effectively improve ovarian function, even continue to maintain menstruation after drug withdrawal. In the real world, Yangyin Shugan Decoction got satisfactory efficacy and good safety in the treatment of POI, which deserves clinical promotion and application.

ключеви́че слова́

premature ovarian insufficiency;Yangyin Shugan Decoction;pattern of kidney deficiency and liver depression;real world;retrospective study

References

  1. [1].
    中华医学会妇产科学分会绝经学组．早发性卵巢功能不全的临床诊疗专家共识(2023版)[J].2023，58(10)：721-728.
  2. [2].
    LI M, ZHU Y, WEI J, et al.The global prevalence of premature ovarian insufficiency：a systematic review and meta analysis[J].Climacteric，2023，26(2)：95-102.
  3. [3].
    陈蓉，罗敏．早发性卵巢功能不全的相关术语[J].中国实用妇科与产科杂志，2023，39(9)：869-871.
  4. [4].
    PANAY N, ANDERSON RA, NAPPI RE, et al. Premature ovarian insufficiency: an International Menopause Society White Paper[J].Climacteric, 2020, 23(5): 426-446.
  5. [5].
    BABER RJ, PANAY N, FENTON A, et al. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy[J]. Climacteric, 2016, 19(2): 109-150.
  6. [6].
    The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society[J]. Menopause, 2017, 24(7): 728-753.
  7. [7].
    中华医学会妇产科学分会绝经学组. 绝经管理与绝经激素治疗中国指南(2018)[J]. 中华妇产科杂志，2018, 53(11): 729-739.
  8. [8].
    CAO XJ, HUANG X, LIU J, et al. A randomized, double-blind, placebo-controlled trial of Chinese herbal medicine capsules for the treatment of premature ovarian insufficiency[J]. Menopause, 2018, 25(8): 918-926.
  9. [9].
    曹晓静，王小云．滋肾调肝法治疗肾虚肝郁型卵巢功能不全的随机对照研究[J].湖北中医杂志，2018，40(1)：9-12.
  10. [10].
    王吉菊，刘建，黄旭春，等．养阴舒肝颗粒对肝郁证模型小鼠行为学及脑内单胺类神经递质的影响[J].中药新药与临床药理，2019，30(1)：47-51.
  11. [11].
    中国中西医结合学会妇产科专业委员会. 早发性卵巢功能不全中西医结合诊疗指南[J]. 中医杂志，2022，63(12): 1193-1198.
  12. [12].
    BILANGES B, POSOR Y, VANHAESEBROECK B. PI3K isoforms in cell signalling andvesicle trafficking[J]. Nat Rev Mol Cell Biol, 2019, 20(9): 515-534.
  13. [13].
    杨珍，魏茂林，董晓英．毓麟珠通过调控FOXO3a通路影响免疫性POI小鼠卵巢功能的机制研究[J].中华中医药杂志，2022，37(10)：6026-6030.
  14. [14].
    李晓红，龙旭，杨卓. 缺氧诱导因子-1α对人卵巢颗粒细胞KGN能量代谢的影响及作用机制研究[J]. 广西医科大学学报，2023, 40(8): 1283-1289.
  15. [15].
    金晓飞，闫婧，赵季宇，等. “秩边透水道”针法对早发性卵巢功能不全大鼠肿瘤坏死因子相关凋亡诱导配体及其受体表达的影响[J]. 针刺研究，2023, 48(3): 259-266.
  16. [16].
    张静，高冬冬，谷灿灿，等．基于MAPK/ERK通路探讨茯苓多糖对卵巢早衰模型大鼠的作用及其分子机制[J].中国现代医学杂志，2024，34(13)：41-48.
  17. [17].
    黄思丹，张怡，张丹妮，等. 基于氧化应激探讨中医药治疗早发性卵巢功能不全的作用机制[J]. 中医药信息，2024, 41(6): 28-34.
  18. [18].
    付靖波，张红霞，朱海英. 颗粒细胞凋亡调控机制及其在卵泡发育中的作用[J]. 中国临床医学，2020, 27(5): 857-860.
  19. [19].
    陈玥，陈思，张蕾，等. 基于雌激素受体途径探讨补肾活血汤干预免疫性卵巢早衰小鼠模型机制研究[J]. 陕西中医，2023, 44(5): 556-561.
  20. [20].
    王叶叶，郭雪桃. 早发性卵巢功能不全患者焦虑和抑郁影响因素分析[J]. 中国妇幼健康研究，2023, 34(12): 70-77.
  21. [21].
    陆岩，黄旭春，曹晓静，等. 基于网络药理学及分子对接技术探讨白芍治疗早发性卵巢功能不全的作用机制[J]. 广州中医药大学学报，2022, 39(6)：1383-1390.
  22. [22].
    张双，周惠芳，刘玉楠，等．加味地黄汤调控Bcl-2相关线粒体凋亡信号通路改善小鼠卵巢储备功能的研究[J].中国中药杂志，2021，46(24)：6493-6501.
  23. [23].
    王敏. 基于氧化应激探讨疏肝补肾法对卵巢早衰大鼠颗粒细胞凋亡的影响[D]. 福州：福建中医药大学，2023.
  24. [24].
    王淼．芬吗通联合高压氧治疗对早发性卵巢功能不全患者改良Kupperman积分、性激素及抗苗勒管激素水平的影响[J].实用妇科内分泌电子杂志，2023，10(30)：72-74.
  25. [25].
    张琴，苏占营，吴成亮．基础性激素联合抗苗勒管激素、窦卵泡数评价生长激素药物治疗早发性卵巢功能不全的效果[J].药品评价，2021，18(18)：1118-1120.
  26. [26].
    魏少奔，王宇慧，武俊丽，等．二仙汤加减联合芬吗通治疗对原发性卵巢功能不全患者生殖内分泌激素及卵巢体积的影响[J].海南医，2023，34(15): 2177-2180.
  27. [27].
    叶子，王菁，刘嘉茵，等. 基础黄体生成素和不同LH/FSH比值水平对PCOS患者辅助生殖妊娠结局的影响[J]. 实用妇产科杂志，2024, 40(3): 213-218.
  28. [28].
    张瑞青，刘莉萍，张瑞湘．调经促孕丸联合西药治疗早发性卵巢功能不全肾阳虚证临床研究[J].新中医，2024，56(18)：93-97.

Читать полностью

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website